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ABSTRACT The cell wall of budding yeast is a rigid structure composed of multiple compo-
nents. To thoroughly understand its involvement in morphogenesis, we used the image anal-
ysis software CalMorph to quantitatively analyze cell morphology after treatment with drugs 
that inhibit different processes during cell wall synthesis. Cells treated with cell wall–affecting 
drugs exhibited broader necks and increased morphological variation. Tunicamycin, which 
inhibits the initial step of N-glycosylation of cell wall mannoproteins, induced morphologies 
similar to those of strains defective in α-mannosylation. The chitin synthase inhibitor nikkomy-
cin Z induced morphological changes similar to those of mutants defective in chitin transgly-
cosylase, possibly due to the critical role of chitin in anchoring the β-glucan network. To de-
fine the mode of action of echinocandin B, a 1,3-β-glucan synthase inhibitor, we compared 
the morphology it induced with mutants of Fks1 that contains the catalytic domain for 1,3-β-
glucan synthesis. Echinocandin B exerted morphological effects similar to those observed in 
some fks1 mutants, with defects in cell polarity and reduced glucan synthesis activity, sug-
gesting that echinocandin B affects not only 1,3-β-glucan synthesis, but also another func-
tional domain. Thus our multivariate analyses reveal discrete functions of cell wall compo-
nents and increase our understanding of the pharmacology of antifungal drugs.
INTRODUCTION
The fungal cell wall is a rigid structure that plays important roles in 
the establishment and maintenance of cell shape (Klis et al., 2006). 
Without the cell wall, fungal cells could not form their unique mor-
phology. Cells of the budding yeast Saccharomyces cerevisiae have 
an oval shape, surrounded by the cell wall formed during vegetative 
cell growth. Dynamic remodeling of the yeast cell wall occurs during 
the cell cycle and is coordinated during cell morphogenetic events, 
including bud emergence, apical bud growth, isotropic bud growth, 
and cell division (Latgé, 2007).
Based on detailed analyses of yeast cell wall composition, it was 
proposed that it exhibits a highly organized dynamic network struc-
ture (Kollár et al., 1997). The cell wall is composed of interconnected 
filamentous polysaccharides and nonfilamentous glycoproteins. A 
major filamentous component is 1,3-β-glucan, whose nonreducing 
ends function as sites for the covalent attachment of other polysac-
charides (Klis et al., 2006). 1,6-β-Glucan is another filamentous com-
ponent, but it is relatively short and a minor component of the cell 
wall. Highly branched 1,6-β-glucan chains are found at the external 
face of the 1,3-β-glucan network. Chitin is an additional minor com-
ponent normally deposited in a ring in the neck between a mother 
cell and its emerging bud, in the primary septum during division, 
and in the lateral walls of newly separated daughter cells, where it 
serves as an anchor for the glucan network (Orlean, 2012). The 
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501 morphometric parameters using CalMorph (Ohtani et al., 2004) 
after treatment with various concentrations of the drugs and per-
formed a principal component analysis (PCA). PCA is an exploratory 
multivariate statistical technique for simplifying complex data sets, 
and it has been used for analyzing the effects of dose-dependent 
changes on morphology (Ohnuki et al., 2012). Figure 1B shows that 
the first principal component (PC1) scores increased in a dose-de-
pendent manner for each of the cell wall–affecting drugs, suggest-
ing that similar morphological changes were progressively more 
apparent in the data sets. Next we performed a second PCA to 
identify dose-dependent parameters that are independent of each 
other (see Materials and Methods). Accordingly, we identified seven, 
eight, and two representative parameters for EB, TM, and NZ, re-
spectively (Supplemental Figures S1 and S2 and Supplemental Ta-
bles S1, a–c, and S2, a–c).
Figure 2 illustrates the morphological changes induced by EB, 
TM, and NZ, in which all representative parameters significantly af-
fected by the drugs are shown (p < 0.0001 after Bonferroni correction 
using the t test), as well as the progression of the cell cycle stages, 
including unbudded cells (G1), budded cells with a single nucleus 
(S/G2), and budded cells with two nuclei (M). Of note, treatment with 
all three drugs resulted in an increased neck width (red). Neck width 
increased at 0.1–0.3 μm with the EB, TM, and NZ treatments (Figures 
1A and 3), suggesting that preservation of the neck structure is a 
major role of the yeast cell wall. In addition to the unique features for 
each cell wall–affecting drug (black), we identified features common 
to EB and TM (green), EB and NZ (blue), and TM and NZ (brown). The 
morphological features induced by TM overlapped with those in-
duced by EB. As reported previously, the proportion of small budded 
cells increased after EB treatment (Drgonová et al., 1999). Cells were 
enlarged after TM treatment, as described previously (Arnold and 
Tanner, 1982). In addition to the known cell morphological changes, 
we found that actin and the nucleus were also affected. The nuclear 
size increased after EB and TM treatment, and actin was delocalized 
in EB- and NZ-treated cells. These quantitative analyses revealed that 
each cell wall component had different and distinct functions in cell, 
actin, and nuclear morphology.
Phenotypic variation after treatment with cell wall–affecting 
drugs
To investigate phenotypic variations, we compared the distribution 
of variance with and without cell wall drugs. Among the parameters 
with notable drug effects (Jonckheere–Terpstra test, p < 0.05), the 
variance was greater in EB-, TM-, and NZ-treated cells (Figure 4, A, 
D, and G). We found that 65% (128/197), 54% (69/127), and 84% 
(31/37) of the parameters showed a broad distribution after treat-
ment with EB, TM, and NZ, respectively. Mother cell size (parameter 
C11-1_A) exhibited marked variance among the five replicates after 
the EB treatment (Figure 4B). Similarly, the long axis in bud (param-
eter C107_C) and mother cell fitness for ellipse (parameter C13_C) 
exhibited greater variance after the TM and NZ treatments, respec-
tively (Figure 4, E and H). Phenotypic variation in each trait can be 
partitioned into the contribution of variations among the cell popu-
lation and measurement errors. Significantly greater variations 
among the cell populations were detected after drug treatments 
(Figure 4, C, F, and I; p < 0.05 after Bonferroni correction, Mann–
Whitney U test), which suggested that phenotypic variation could 
be explained in part by variation in the cell population.
Effects of EB, TM, and NZ on cell morphology
To compare the effects of the cell wall–affecting drugs, we plotted 
dose-dependent morphological changes in a two-dimensional (2D) 
major nonfilamentous cell wall components are mannoproteins, 
which are mannose-containing glycoproteins. These heavily glycosy-
lated proteins are typically found on the exterior of the cell wall. 
Most mannoproteins are glycosylphosphatidylinositol–anchored 
proteins and are connected to 1,6-β-glucan chains. Thus, covalent 
linkages between the various components of the cell wall give rise to 
its elastic and plastic properties, providing a strong, continuous 
fabric.
The fact that the different types of yeast cell wall components are 
interconnected suggests that the disruption of individual cell wall 
biosynthetic pathways would result in similar morphological pheno-
types. Alternatively, the contribution of different components to cell 
morphology may differ because the physical strength and flexibility 
of the filamentous and nonfilamentous components vary. Several 
studies examined the effects of perturbing the synthesis or the 
cross-linking of cell wall components (de Groot et al., 2001; 
Nishiyama et al., 2002; Schmidt et al., 2003, 2005; Blanco et al., 
2012). However, qualitative observation by eye has limited power to 
resolve the morphological differences caused by the mutation of 
genes encoding the enzymes involved in cell wall synthesis. To date, 
no quantitative morphological analyses of cell wall mutant strains 
have been performed.
To examine yeast cell morphology quantitatively, we developed 
an automatic image processing system called CalMorph (Ohtani 
et al., 2004). This system is a high-throughput, high-resolution im-
age processing software package that enables the quantification of 
501 cell morphology parameters from fluorescence images of the 
cell wall, actin, and nuclear DNA of yeast cells (Ohya et al., 2005). 
On the basis of a morphological analysis of the 4718 haploid nones-
sential gene deletion mutants, we created a morphological data-
base named the Saccharomyces cerevisiae Morphological Database 
(SCMD; http://yeast.gi.k.u-tokyo.ac.jp; Saito et al., 2004). Analysis 
of the data for this large set of mutants revealed significant new re-
lationships between morphological phenotypes and gene functions 
(Ohya et al., 2005). Further detailed phenotypic analysis of clusters 
of mutants with similar phenotypes revealed new insights into com-
plex cellular pathways (Ohnuki et al., 2007; Okada et al., 2010; 
Yoshida et al., 2013). In addition, we were able to predict the intrac-
ellular targets of specific drugs by comparing their morphological 
effects to the database (Ohnuki et al., 2010; Iwaki et al., 2013).
To gain further insight into the involvement of the cell wall in 
morphogenesis, we quantitatively analyzed the morphological 
changes induced by echinocandin B (EB), tunicamycin (TM), and nik-
komycin Z (NZ), drugs that block cell wall biosynthesis pathways. 
Specifically, EB is a noncompetitive inhibitor of 1,3-β-glucan syn-
thase (GS; Sawistowska-Schröder et al., 1984; Douglas, 2001), TM 
targets N-acetylglucosamine (GlcNAc) phosphotransferase, which 
plays a role in the biosynthesis of mannoproteins (Barnes et al., 
1984), and NZ is a competitive inhibitor of chitin synthase (Cabib, 
1991). Multivariate analyses of the morphological changes induced 
by these drugs, as well as a comparison of the cell wall mutants, re-
vealed discrete functions of the cell wall components in determining 
cell morphology.
RESULTS
Morphological effects of cell wall–affecting drugs
The morphological effects of treating haploid yeast with drugs that 
perturb the cell wall (EB, TM, and NZ) were examined by using fluo-
rescence microscopy to observe the cell wall, actin, and nuclear 
DNA. Visual inspection revealed that cells treated with 4 μg/ml EB, 
100 ng/ml TM, and 400 μM NZ exhibited abnormal morphologies 
(Figure 1A). To explore the dose-dependent changes, we quantified 
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the nonessential deletion mutants with defects in cell wall–related 
genes (Lesage and Bussey, 2006; Orlean, 2012). The deletion mu-
tants of the cell wall targets should have similar morphological pro-
files as cells treated with the cell wall–affecting drugs.
The morphological profiles induced by the TM treatment showed 
significant similarities to those induced by individual deletions of 
five genes (MNN10, ANP1, OCH1, MNN2, and HOC1) that encode 
mannosyltransferase in the Golgi (Figure 6; p < 0.05 after Bonferroni 
correction, t test). The correlation coefficient for mnn10 was 0.59. 
TM-treated cells were also similar to mutants of cax4, a dolichyl 
pyrophosphate phosphatase that supplies dolichol-linked oligosac-
charide substrates for N-glycosylation in the endoplasmic reticulum 
(ER; van Berkel et al., 1999). The Gene Ontology term analysis with 
the significantly similar 85 gene deletion mutants (p < 0.0001 after 
Bonferroni correction, t test) showed enrichment of α-1,6-
mannosyltransferase activity (Supplemental Table S4). These results 
are consistent with the mode of action of TM, which blocks N-glyco-
sylation (Ballou, 1990; Jigami, 2008).
Of the three chitin synthase mutants, only the chs1 and chs3 
mutants were viable and therefore testable in our assay. Neither 
of these mutants was morphologically similar to NZ-treated cells, 
probably because NZ targets more than one chitin synthase in 
vivo. NZ-treated cells were morphologically similar to the utr2 
(crh2) mutant (Figure 6; r = 0.42), which was defective for the ma-
jor chitin transglycosylase that functions in the transfer of chitin to 
1,3-β- and 1,6-β-glucans (Cabib et al., 2007). In contrast, the mor-
phologies of the crh1 mutant (defective in minor chitin transglyco-
sylase) and the crr1 mutant (defective in cross-linking during 
space of “similarity” and “dissimilarity.” Similar parameters were de-
fined as those with the same direction of changes after treatment 
with the two drugs, whereas dissimilar parameters exhibited changes 
in the opposite direction (see Materials and Methods). As shown in 
Figure 5A, similar and dissimilar parameters were located in the 
first/third quadrants and second/fourth quadrants, respectively. 
Representative similar and dissimilar features were then extracted 
by reducing the dimensions by PCA (Figure 5B and Supplemental 
Figure S3).
The EB and TM treatments are compared in Figure 5C. The EB 
treatment decreased from the point of origin, but the TM treatment 
increased with increasing concentrations, separating the effects of 
the two drugs. Treatment with micafungin, another GS inhibitor, also 
decreased, similar to EB. Given that micafungin had similar effects 
to EB, drugs with the same activity showed similar behavior in the 
similar/dissimilar 2D space.
We also compared EB and NZ treatments and TM and NZ treat-
ments (Supplemental Figure S4). Supplemental Figure S4A shows 
that EB, NZ, and TM behaved differently but that micafungin acted 
similarly to EB. TM, NZ, and EB also worked differently in the similar/
dissimilar 2D space (Supplemental Figure S4B). Therefore EB, TM, 
and NZ had distinct effects on cell morphology, as expected from 
their rather different cellular effects.
Nonessential deletion mutants with morphologies similar 
to those induced by drug treatments
To validate the analytical system, we compared the morphological 
profile of cells treated with the cell wall–affecting drugs to those of 
FIGURE 1: Morphological changes induced by cell wall–affecting drugs. (A) Wild-type strains were cultured until the 
early log phase at 25°C in YPD with EB or TM, and in SD with NZ at the indicated concentrations. Cells were stained 
with fluorescein isothiocyanate–concanavalin A (green), rhodamine–phalloidin (red), or 4′,6-diamidino-2-phenylindole 
(blue) to visualize the cell wall, actin, or nucleus, respectively. Bar, 5 μm. (B) Dose-dependent changes in PC1 scores. 
Morphological data on cells treated with various concentrations of the drugs (n = 5) were subjected to PCA.
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critical role that chitin plays in the anchoring of the β-glucan 
network.
However, EB-treated cells had no resemblance to the deletion 
mutants of the major (Fks1) and minor (Fks2) subunits of GS (Figure 
6). This is consistent with previous observations (Ohnuki et al., 2010; 
sporulation) were different from NZ-treated cells (Rodríguez-Peña 
et al., 2000; Gómez-Esquer et al., 2004; Cabib et al., 2007). NZ-
treated cells were also morphologically similar to mutants lacking 
CHS5 (Figure 6), which is involved in the trafficking of Chs3 and 
Utr2 (Rodríguez-Peña et al., 2002). These results highlight the 
FIGURE 2: Summary of the morphological changes induced by cell wall–affecting drugs. Morphological changes 
induced by the drugs were analyzed using two-step PCA to identify representative parameters for each drug (see 
Materials and Methods). Representative parameters for each drug (underlined) and those identified for another drug 
but significantly affected by the indicated drugs are shown with illustrations of the cells (Jonckheere–Terpstra test; 
<1 false positive was detected by chance at p = 0.0013, 0.0052, and 0.0033 for EB, TM, and NZ, respectively; 
Supplemental Table S3). Colored text indicates shared morphological features among drugs; red, green, blue, and 
brown represent features shared by EB–TM–NZ, EB–TM, EB–NZ, and TM–NZ , respectively. Asterisks denote features 
shared by EB and fks1-ts mutants; single, double, and triple asterisks indicate features shared by EB and class I and III, 
class II, and class II and III, respectively (Supplemental Table S5).
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treatment (Figure 8), suggesting that EB influenced the regulation 
of cell polarity by inhibiting Spa2 localization, similar to class II 
mutants.
We next compared the morphological phenotypes of EB-treated 
cells with those of the class II and class III mutants. Among the sev-
eral morphological features of EB-treated cells (Figure 2), either in-
creased cell size or increased ratio of cells with small buds was ob-
served in class II or class III mutants, respectively (Supplemental 
Table S5). The increased ratio of cells with delocalized actin was 
common to both classes (Supplemental Table S5). Thus some of the 
morphological parameters influenced by EB are also affected in 
class II and III mutants.
EB affects both class II and III domains
Recent topological analysis revealed that EB-resistance mutations 
accumulated as affected clusters of residues called hot spots at the 
extracellular surface of Fks1 (Johnson and Edlind, 2012). Hot spots 
1–3 are located at amino acid residues of 635–649, 1354–1361, and 
690–700, respectively, of Fks1 (Supplemental Table S6). Because 
these hot spots are considered to be the sites for direct interaction 
with EB, it is significant that class II and III mutations affected resi-
dues near these hot spots in the primary structure of Fks1p (Figure 
7A and Supplemental Table S6). To determine whether EB inhibited 
the function of both class II and class III mutants, we examined the 
EB sensitivity of each class of GS mutants. Both class II (fks1-1163) 
and class III (fks1-1154) mutants failed to grow in the presence of 
0.5 μg/ml EB, indicating an EB-sensitive phenotype (Figure 9). In 
contrast, wild-type and class I mutants (fks1-1082) were capable of 
growth in the presence of 0.5 μg/ml EB. These results suggested 
that EB affected the functions of the regions of Fks1 that are altered 
by the class II and class III mutations.
We next determined whether the fks1 mutants with both class II 
and III defects were lethal. For this purpose, we constructed strains 
harboring single-domain (fks1-1163 and fks1-1154) and double-do-
main (fks1-11631154) mutations after a galactose-inducible FKS1 
gene was introduced on a plasmid. We found that the double-do-
main mutants failed to grow even at 25°C, suggesting that class II 
and III domains had synergistic effects on the function of Fks1 (Sup-
plemental Figure S7). Thus EB affected two related and important 
functions of Fks1: 1,3-β-glucan synthesis and cell polarity.
DISCUSSION
We used three drugs (EB, TM, and NZ) that cause distinct types of 
cell wall damage by inhibiting known targets to characterize the 
morphological changes induced by inhibiting the biosynthesis of 
the three major cell wall components, 1,3-β-glucan, mannoproteins, 
and chitin, in S. cerevisiae. Treatment with the three drugs induced 
several common morphological effects, including increased neck 
width and morphological variation. However, they also exhibited 
different effects on cell morphology, indicative of the distinct roles 
played by the cell wall components in cell morphogenesis. Results 
of chemical–genetic approaches using TM and NZ were consistent 
with the classical genetic approach, demonstrating that N-linked 
glycosylation and glucan/chitin cross-linking were important for 
morphogenesis. Moreover, EB had pleiotropic effects on cell mor-
phology and affected multiple functions of Fks1, including mainte-
nance of cell polarity and 1,3-β-glucan synthesis.
N-glycosylation pathway and cell morphogenesis
Statistical analysis revealed that the TM treatment induced several 
morphological features. Eight representative parameters were 
affected in a dose-dependent manner after treatment with TM 
Okada et al., 2010) and is probably due to functional redundancy 
between Fks1 and Fks2 and/or the multifunctional properties of 
Fks1 (Ohnuki et al., 2010; Okada et al., 2010). Mutants subsets re-
lated to α-1,6-mannosyltransferase were enriched in 84 significantly 
similar mutants to EB-treated cells (p < 0.0001 after Bonferroni cor-
rection, t test; Supplemental Table S4), perhaps because EB- and 
TM-treated cells were somewhat similar.
Morphological similarities with temperature-sensitive 
fks1 mutants
Because EB-treated cells were not similar to fks1Δ or fks2Δ deletion 
mutants, we compared them with the morphological profiles of 
temperature-sensitive GS mutants. Because FKS1 and FKS2 are re-
dundant genes, we previously created 10 temperature-sensitive 
fks1 alleles in an fks2Δ-mutant strain background (Figure 7A; Okada 
et al., 2010). These mutants were classified into three groups 
(Classes I–III) according to their different phenotypes. After PCA 
analysis, the morphological profiles of the fks1 mutants were de-
picted in a 2D space that described the variety of mutant pheno-
types (Figure 7B and Supplemental Figure S5). EB affects GS activity 
(Sawistowska-Schröder et al., 1984; Douglas, 2001). Because class 
III mutants showed decreased GS activity, we predicted that EB-
treated cells would resemble class III mutants. However, the map-
ping of PC scores of EB-treated cells indicated similarity to the class 
II mutants (Figure 7B). Class II mutants showed normal GS activity 
and exhibited loss of Spa2 localization (Okada et al., 2010). Because 
Spa2 is a component of the polarisome (Snyder, 1989; van Drogen 
and Peter, 2002), loss of Spa2 localization is indicative of a cell polar-
ity defect in class II mutants.
To determine whether EB-treated cells had a cell polarity de-
fect, we assessed the localization of Spa2–green fluorescent pro-
tein (GFP) in living cells. We confirmed that Spa2 localization was 
lost in class II but not in class III mutants (Supplemental Figure S6), 
consistent with previous observations (Okada et al., 2010). We also 
found that Spa2–GFP localization decreased significantly after EB 
FIGURE 3: Effect of cell wall–affecting drugs on neck width (C109_
A1B). Morphological changes induced by treatment with (indicated 
concentrations) or without (control) the highest drug concentrations 
are plotted. Asterisk indicates significant difference (p < 0.05 by 
Mann–Whitney U test after Bonferroni correction).
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the TM treatment showed significant similarity to individual dele-
tions of the genes encoding mannosyltransferase in the Golgi, as 
well as cax4, die2, and ost6, which mediate N-glycosylation in the 
ER. TM-treated cells were similar to an och1 mutant (a mutant of 
cis-Golgi α-1,6-mannosyltransferase), deletion mutants of Golgi 
α-1,6-mannosyltransferase and the M-pol II complex (mnn10, 
(Supplemental Table S2b). For example, mother and daughter cells 
enlarged, nuclear size increased in unbudded cells, and the neck 
width increased. The increase in cell size was reported previously 
(Arnold and Tanner, 1982).
TM blocks the initial step of N-glycosylation by inhibiting Alg7 in 
the ER (Barnes et al., 1984). The morphological profile induced by 
FIGURE 4: Marked morphological variation among drug-treated yeast populations. (A, D, G) Variance in the 
morphological parameters affected by the drugs (A, EB; D, TM; and G, NZ) was plotted in the highest to lowest order. 
Black and gray circles indicate parameters of higher and lower variance compared with the control (=1, dashed line), 
respectively. Red circles denote morphological parameters exemplified in B, E, and H. (B, E, H) Examples of 
morphological parameters with increased variance upon EB, TM, and NZ treatment. (C, F, I) Distributions of 
morphological parameters exemplified in B, E, and H visualized using a box plot with single-cell resolution. Gray and 
white boxes denote single-cell distribution with and without drug treatment, respectively.
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phenotype was reported previously (Schmidt et al., 2003). Note that 
no changes in nuclear morphology were detected.
Chitin is a polymer of 1,4-β-linked GlcNAc, contributing only 
1–2% of the dry weight of the cell wall (Lesage and Bussey, 2006), 
which serves as a scaffold for anchoring 1,3-β- and 1,6-β-glucans. 
Chitin occurs in three different and polydispersed forms in the wall. 
In addition to free chitin, some is bound to 1,3-β-glucan and is pres-
ent predominantly in the neck region, whereas a lesser amount is 
found in lateral walls bound to 1,6-β-glucan (Cabib and Durán, 
2005; Cabib, 2009). We found that NZ-treated cells were morpho-
logically similar to utr2, which was defective in glucan/chitin cross-
linking (Cabib et al., 2007; Cabib, 2009). In addition, chs5 and pfa4 
mutants, but not chs3, chs6, or chs7, all of which contain reduced 
levels of chitin, also showed a significant correlation with the NZ 
treatment cells. Of interest, only chs5 and pfa4 have additional de-
fects on the intracellular traffic of other proteins, including the mis-
localization of Utr2 in the chs5 mutant (Rodríguez-Peña et al., 2002). 
These results highlight the critical role of the chitin–glucan linkage in 
morphogenesis, in clear agreement with a recent proposal (Cabib 
and Arroyo, 2013), but also uncover a redundant role of the different 
chitin synthases in forming the chitin–glucan network.
EB affects multiple functions of Fks1
Echinocandin-family drugs (e.g., EB and micafungin) noncompeti-
tively inhibit incorporation of UDP-glucose into 1,3-β-glucan 
anp1, and hoc1), and a mnn2 mutant (a mutant of α-1,2-
mannosyltransferase), which are defective in the first, third, and 
fourth steps, respectively, of outer-chain elongation of N-linked oli-
gosaccharides in the Golgi (Jigami, 2008). Mnn9 is also a compo-
nent of M-pol II (A complex), but forms another mannosyltransferase 
complex known as M-pol I (V complex), which functions in the sec-
ond step with Van1 (Hashimoto and Yoda, 1997; Jungmann and 
Munro, 1998; Jungmann et al., 1999). Given that the morphological 
phenotypes of mnn9 and van1 differ from that of TM-treated cells, 
M-pol I may play additional roles in cell morphogenesis.
Loss of mannosyltransferase activity reduces protein mannosyla-
tion (Lagunas et al., 1986). Mutants defective in early glycosylation 
reactions exhibit aberrant cell wall assembly (Orłowski et al., 2007). 
These results suggest that N-glycosylation is necessary for the activ-
ity or stability of the proteins responsible for cell wall assembly. Un-
expectedly, we found that the effects of TM treatment were similar 
to the effects caused by the single-gene deletion of Ccw12 (Figure 
6; r = 0.66), highlighting the role of this mannoprotein in cell wall 
function (Mrsa et al., 1999; Ragni et al., 2011).
Chitin synthesis and cell morphogenesis
NZ had no severe effects on S. cerevisiae growth, and therefore its 
effect on cell morphology was expectedly minor. We found that 
neck width and bud roundness increased, whereas the ratio of 
unbudded cells with localized actin decreased. The wide-neck 
FIGURE 5: Similarity and dissimilarity of the effects of the drugs on cell morphology. (A) Distribution of loadings for PC1 
after PCA of the EB and TM data. Of the 501 parameters, 369 were defined as similar (red symbols) due to their 
distribution in the first/third quadrants; otherwise, 132 were dissimilar parameters that were distributed in the second/
fourth quadrants (blue symbols). (B) Schematic representation of the extraction of similar/dissimilar effects on drug 
treatment. Morphological parameters were assigned to similar or dissimilar parameters based on the loading sign and 
independently subjected to the second PCA. Dose-dependent effects of the drugs were then visualized in a similar/
dissimilar 2D space. (C) Similar and dissimilar effects of EB and TM on cell morphology. Morphological changes induced 
by NZ and micafungin were mapped onto the 2D space. The grayscale indicates the doses of drugs used (from dilute to 
concentrated).
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FIGURE 6: Morphological profiling of the cell wall–affecting drugs. The drug-induced morphological profiles were 
compared with 4718 mutants of nonessential genes, as described previously (Ohnuki et al., 2010). The vertical axis 
indicates the similarity to each gene deletion mutant as a –log10 p value of a correlation coefficient (t test). The 
horizontal dashed line shows the threshold of p = 1.06 × 10−5 corresponding to a one-sided p = 0.05 after Bonferroni 
correction. Red dots denote cell wall–associated mutants (Lesage and Bussey, 2006; Orlean, 2012), with morphological 
profiles similar to those of drug-treated cells. Right, representative photographs of wild-type cells after drug treatment 
and representative deletion mutants (fks1, mnn10, and utr2). R is the correlation coefficient between drug-treated and 
mutant cells. Bar, 5 μm.
0 1000 2000 3000 4000
0
5
10
15
ORF in alphabetical order
−
lo
g 1
0
p
fks1
fks2 fks3
0 1000 2000 3000 4000
0
5
10
15
ORF in alphabetical order
−
lo
g 1
0
p mnn10 anp1 hoc1
ccw12
och1
van1
mnn9
mnn2 die2
ost6
cax4
0 1000 2000 3000 4000
0
5
10
15
ORF in alphabetical order
−
lo
g 1
0
p
chs1
chs3 chs7 chs6
pfa4chs5
crh1
utr2
crr1
fks1EB
R = 0.26
mnn10TM
R = 0.59
utr2NZ
R = 0.42
1,3-β-glucan synthesis
N-glycosylation
Chitin synthesis & processing
FIGURE 7: Morphological phenotypes of EB-treated and fks1 cells. (A) Functional map of Fks1p (modified from Okada 
et al., 2010). The gray-hatched box denotes the plasma membrane. Red symbols on the black line indicate hot spots (the 
echinocandin resistance–conferring mutations). The amino acids mutated and the hot spots are listed in Supplemental 
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indicates the dose of EB used (from dilute to concentrated). PC1 and PC2 explained ∼60% of the variance.
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Preservation of the neck structure 
of the cell wall
We demonstrated that yeast cells had a 
broadened neck width after treatment with 
all cell wall–affecting drugs, suggesting that 
maintaining a narrow neck is a common 
function performed by cell wall compo-
nents. Phenotypic analysis of several cell 
wall mutants supported this hypothesis. 
Mutation of genes involved in the outer-
chain elongation of N-linked oligosaccha-
rides in the Golgi (OCH1, MNN10, ANP1, 
and MNN2), CAX4 (N-glycosylation in the 
ER), and CCW12 (mannoprotein) resulted 
in significantly wider necks (data available 
at SCMD). Chs5, which is involved in the 
export of chitin synthase (Santos and 
Snyder, 1997; Santos et al., 1997), Kre6, 
which is required for 1,6-β-glucan biosyn-
thesis (Roemer and Bussey, 1991), and 
1,3-β-glucanosyltransferase (Gas1), which is 
required for cell wall assembly; Ram et al., 
1998; Popolo and Vai, 1999), were also all 
necessary to maintain a narrow neck (data 
available at SCMD). Thus classical genetic 
and chemical–genetic approaches both re-
sulted in common morphological phenotypes induced by the lesion 
of cell wall components.
All components of the yeast cell wall are localized at or near the 
bud neck. The filamentous components 1,3-β-glucan and 1,6-β-
glucan are found on the interior of the cell wall around a constriction 
between the mother and daughter cells. Nonfilamentous compo-
nent mannoproteins are also localized to this region on the exterior 
surface. In contrast, chitin is localized at the bud/birth scar and the 
primary septum. Several explanations of the wide-neck phenotypes 
caused by cell wall–affecting drugs are possible. Physical strength is 
presumably required to maintain the curvature structure of the neck. 
If the network structure of the cell wall is weakened, it may lead to 
morphological changes of the neck. Alternatively, neck morphology 
may be determined by many genes, among which those encoding 
enzymes responsible for synthesis of cell wall components may play 
important roles. Further studies are required to clarify the molecular 
mechanism underlying neck morphogenesis and demonstrate how 
it is related to cell wall functions.
(Douglas, 2001). This has not been demonstrated directly, but sev-
eral lines of evidence suggest that Fks1 is a direct target of echi-
nocandins. For example, Fks1 is a putative catalytic subunit of GS 
(Inoue et al., 1995; Drgonová et al., 1996; Qadota et al., 1996); hot 
spots—regions of the mutations conferring strong echinocandin re-
sistance—exist exclusively in Fks1 (Douglas, 2001; Perlin, 2007; 
Johnson et al., 2011); and specific mutations within these hot spots 
result in differential echinocandin resistance (Johnson et al., 2011; 
Healey et al., 2012).
Here we demonstrated that EB more strongly affected class II 
and III fks1 mutants, which carry substitutions in the cytosolic region. 
Johnson and Edlind (2012) reported that the three hot spots for 
echinocandin-resistance mutations affect residues that are located 
externally and proposed that all hot spot residues are juxtaposed in 
the three-dimensional structure of Fks1 to form a single echinocan-
din-binding pocket. Of interest, the residues affected by the class II 
and III mutations are adjacent to the hot spots, which suggests that 
binding of EB affects the central cytosolic domains of Fks1.
FIGURE 8: Effect of EB on Spa2–GFP localization. (A) YOC5002 (spa2 [Spa2–GFP]) cells were 
incubated at 25ºC in SD–U medium with EB (1 μg/ml) or DMSO (control solvent) until the early 
log phase. Cells were then harvested and observed without fixation. The arrowhead indicates 
the absence of Spa2–GFP localization in the bud. Bar, 5 μm. (B) Spa2–GFP localized cells were 
enumerated in three independent experiments. The mean of the triplicates is plotted. Error bars 
denote 1 standard deviation. Asterisk indicates significant difference (p < 0.05 by t test after 
Bonferroni correction).
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of 10 mM NZ (Sigma-Aldrich) and 10 mg/ml micafungin (Astellas 
Pharma, Tokyo, Japan) were prepared in distilled water.
Quantification of the effects of drug treatment on cell 
morphology
Wild-type yeast strains were cultured at 25°C in YPD until the early 
log phase (∼16 h) with 0, 1, 2, 3, or 4 μg/ml EB; 0, 20, 40, 60, 80, or 
100 ng/ml TM; or 0, 10, 15, 20, 25, or 30 ng/ml micafungin. Strains 
treated with NZ (0, 80, 160, 240, 320, or 400 μM) were cultured in 
SD. The concentrations of cell wall–affecting drugs were determined 
based on the growth inhibition rates (∼10%, excluding NZ, which 
did not significantly inhibit the growth of S. cerevisiae). Cell fixation, 
staining, and observation were performed as described previously 
(Ohnuki et al., 2012). Images were analyzed using the image pro-
cessing software CalMorph (version 1.2), which extracted a total of 
501 morphological quantitative values from at least 200 individual 
cells in each experiment. Images were processed using Photoshop 
CS2 (Adobe Systems, San Jose, CA) for illustrative purposes.
Statistical analysis
Morphological profiling of the drugs using the Jonckheere–Terpstra 
test was performed to assess the morphological similarity between 
the cells treated with the cell wall–affecting drugs and nonessential 
deletion mutants (Jonckheere, 1954; Ohnuki et al., 2010). Other sta-
tistical analyses, including PCA, were performed using R, version 
2.14.0 (www.r-project.org/).
Two-step PCA
Before applying PCA to morphological parameters, we transformed 
five replicated parameters to rank-sum values to unify the distribu-
tion of each parameter, as described previously (Ohnuki et al., 2012). 
PCA was performed using the prcomp of the R function without 
scaling.
To identify independent morphological features induced by the 
drugs, we performed a two-step PCA, as described previously 
(Ohnuki et al., 2012). In the first PCA, morphological data on cells 
treated with the drugs were subjected to PCA (Supplemental Figure 
S1). The dose-dependent parameters were correlated with the first 
principal component (PC1) significantly (Supplemental Table S1, a–c) 
and had high absolute loading values to PC1. Of the 501 parame-
ters, significant PC loadings in PC1 were observed for 265, 168, and 
eight parameters in the EB, TM, and NZ data sets, respectively (false 
discovery rate = 0.1 by t test). In the second PCA, data obtained 
from 122 replicated experiments of wild-type cells (null-distributed 
data) in the correlated parameters were subjected to PCA after 
Box–Cox power transformation. The parameter-correlating PCs in 
the second PCA, explaining 60% of the variance, had significant 
loadings (>0.5) at p < 0.0001 based on the t test after Bonferroni 
correction (Supplemental Figure S2, A and B). Several independent 
PCs, named in alphabetical order (e.g., PC1, PC2, and PC3 were 
named PC1a, PC1b, and PC1c, respectively), were extracted for 
each drug (Supplemental Table S2, a–c). One or two dose-depen-
dent parameters of the various morphological criteria were selected 
as representative parameters after taking the absolute loading val-
ues to each PC (>0.5) and the meaning of the parameters (colored in 
yellow in Supplemental Table S2, a–c) into account.
Estimation of the variation in cell morphology
Parameters showing notable dose-dependent drug effects were de-
tected using the Jonckheere–Terpstra test (p < 0.05). Of the de-
tected parameters (354 parameters in EB, 241 in TM, and 87 in NZ), 
the “mean” parameters (197, 127, and 37 parameters, respectively) 
Contribution of the cell wall to phenotypic robustness
We demonstrated that yeast cells were highly morphologically vari-
able after perturbation of the cell wall components. We found sig-
nificantly greater variations between the cell populations after treat-
ment with cell wall–affecting drugs. Levy and Siegal (2008) identified 
yeast deletion mutants with highly variable phenotypes. In their 
study, the anp1 mutant exhibited the second-highest variability in 
overall morphology and mnn10 the 14th highest among all nones-
sential deletion mutants. Mutants (och1, hoc1, mnn2, cax4, and 
ccw12) defective in the mannoproteins, gas1, and kre6 were also 
identified to be highly variable. Although the molecular mechanism 
is unclear, the cell wall structure likely provides robustness to the cell 
by protecting the intracellular functional network from environmen-
tal conditions.
Multivariate analysis to explore complex phenotypes
We used several multivariate approaches to investigate the com-
plex phenotypes induced by cell wall–affecting drugs. To identify 
the morphological features after obtaining high-dimensional mor-
phology data, we performed two-step PCA (Ohnuki et al., 2012). 
This approach allowed us to demonstrate that all cell wall compo-
nents had roles in the preservation of the neck structure and pheno-
typic robustness. To predict the gene deletion mutant whose mor-
phological profile would be similar to that of the drug-treated cells, 
we used a high-content, image-based profiling method (Ohnuki 
et al., 2010), which validated our analysis and indicated a similar 
function of chitin synthesis for chitin transglycosylase in morphogen-
esis. A combination of genetic and statistical analyses facilitated 
examination of the complex effects of cell wall–affecting drugs. Us-
ing these approaches, we determined the mode of action of EB 
using temperature-sensitive fks1 mutants, which showed specific 
loss of the individual functions of Fks1.
Cell wall biosynthesis is a tightly coordinated dynamic biological 
process. Our results suggest mechanistic roles of the cell wall com-
ponents in cell morphogenesis and increase our understanding of 
novel functions of the cell wall and the pharmacology of antifungal 
drugs. A similar approach could be used to investigate the functions 
of other cellular components in cell morphology.
MATERIALS AND METHODS
Strains and plasmids
The yeast strains and plasmids used in this study are listed in Sup-
plemental Tables S7 and S8 and are deposited with the National 
BioResource Project Japan, Yeast Genetic Resource Center (Osaka, 
Japan). The fks1 mutants were constructed as described previously 
(Okada et al., 2010). Y02458 (as BY4741 his3::KanMX) was used as 
the wild-type strain. Standard procedures were used for all DNA 
manipulations and Escherichia coli transformations (Sambrook et al., 
1989).
Media and reagents
Yeast-rich medium (YPD) contained 1% Bacto yeast extract (BD Bio-
sciences, San Jose, CA), 2% Bacto peptone (BD Biosciences), and 
2% glucose. Yeast synthetic medium (SD or SGS) contained 0.66% 
Bacto yeast nitrogen base lacking amino acids (BD Biosciences), 2% 
glucose (SD) or 2% galactose, plus 0.2% sucrose (SGS), and was 
supplemented with the appropriate nutrients. Luria–Bertani medium 
for E. coli contained 1% Bacto tryptone (BD Biosciences), 0.5% Bacto 
yeast extract, and 1% NaCl. Stock solutions of 2 mg/ml EB (a gift 
from O. Kondo, Chugai Pharmaceutical, Tokyo, Japan) or 10 mg/ml 
TM (Sigma-Aldrich, St. Louis, MO) were prepared in dimethyl sulfox-
ide (DMSO; Wako Pure Chemical Industries, Osaka, Japan). Stocks 
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representing the population average were analyzed further. The 
data on cells treated with a high concentration of drugs (4 μg/ml EB, 
100 ng/ml TM, and 400 μM NZ; n = 5) were centered by subtracting 
the mean and scaled by dividing by the standard deviation of the 
control cells without drug treatment (n = 5) and then used to assess 
the effects of the drugs on cell morphology.
Extraction of similar/dissimilar effects of drug treatments
After PCA on the morphological data for the drug-treated cells, the 
loadings of 501 traits for PC1 were plotted on the 2D space of two 
or three arbitrary drugs. Because PC1 scores of all three drugs in-
creased in a dose-dependent manner, we assumed that the traits 
correlating with PC1 in the same direction (a positive or negative 
correlation) between the drugs reflected similar effects. Conversely, 
traits in different directions reflected dissimilar effects. For pairwise 
comparisons among the three drugs (EB–TM, EB–NZ, and TM–NZ), 
we defined similar parameters (369, 289, and 293 traits) and dissimi-
lar parameters (132, 212, and 208 traits, respectively) from 501 traits 
based on the loadings. To identify the primary effects of the drugs 
on each set of similar/dissimilar parameters, we applied PCA inde-
pendently (Supplemental Figure S3) and visualized the distribution 
of PC1 scores.
Spa2 localization
To assess Spa2 localization, we constructed a plasmid expressing a 
Spa2–GFP fusion protein with GFP conjugated immediately before 
the stop codon. A DNA fragment of the SPA2 open reading frame, 
with its 0.5-kb-upstream region, was amplified from the S. cerevisiae 
genome by PCR using primers that generated a SmaI restriction site 
at each end. The PCR product was cloned into a low-copy plasmid 
harboring the URA3 marker and GFP-coding sequence with an FKS1 
terminator to make pYO2642. pYO2642 was then used to transform 
Y01509, YOC1001, YOC1087, and YOC1089 on SD-without-uracil 
(SD–U) plates to obtain YOC5002 and YOC5041–5043, respectively. 
YOC5002 was cultured at 25ºC in liquid SD–U with EB (1 μg/ml) or 
DMSO (control solvent) until the early log phase and harvested. 
YOC5041–5043 were cultured with SD–U at 25ºC until early log 
phase, followed by additional incubation at 37ºC for 2 h. After a 
brief sonication of cells, Spa2–GFP localization was observed using 
fluorescence microscopy.
ACKNOWLEDGMENTS
We thank Osamu Kondo for providing EB, Satoru Nogami for initiat-
ing analysis of the morphology data, and members of the Labora-
tory of Signal Transduction for helpful discussions. This work was 
supported by Grants-in-Aid for Scientific Research from the Ministry 
of Education, Culture, Sports, Science and Technology, Japan 
(21310127 and 24370002 to Y.O.), a grant from the Comisión Inter-
ministerial de Ciencia y Tecnología, Spain (BFU2010-18632 to C.R.), 
and a Public Health Service grant from the National Institute of 
Allergy and Infectious Diseases (AI-47837 to J.B.K.). H.O. and S.O. 
were Research Fellows of the Japan Society for the Promotion of 
Science.
Blanco N, Reidy M, Arroyo J, Cabib E (2012). Crosslinks in the cell wall of 
budding yeast control morphogenesis at the mother-bud neck. J Cell 
Sci 125, 5781–5789.
Cabib E (1991). Differential inhibition of chitin synthetases 1 and 2 from 
Saccharomyces cerevisiae by polyoxin D and nikkomycins. Antimicrob 
Agents Chemother 35, 170–173.
Cabib E (2009). Two novel techniques for determination of polysaccharide 
cross-links show that Crh1p and Crh2p attach chitin to both beta(1-6)- 
and beta(1-3)glucan in the Saccharomyces cerevisiae cell wall. Eukaryot 
Cell 8, 1626–1636.
Cabib E, Arroyo J (2013). How carbohydrates sculpt cells: chemical control 
of morphogenesis in the yeast cell wall. Nat Rev Microbiol 11, 648–655.
Cabib E, Blanco N, Grau C, Rodríguez-Peña JM, Arroyo J (2007). Crh1p and 
Crh2p are required for the cross-linking of chitin to beta(1-6)glucan in 
the Saccharomyces cerevisiae cell wall. Mol Microbiol 63, 921–935.
Cabib E, Durán A (2005). Synthase III-dependent chitin is bound to different 
acceptors depending on location on the cell wall of budding yeast. J 
Biol Chem 280, 9170–9179.
de Groot PW et al. (2001). A genomic approach for the identification and 
classification of genes involved in cell wall formation and its regulation 
in Saccharomyces cerevisiae. Comp Funct Genomics 2, 124–142.
Douglas CM (2001). Fungal beta(1,3)-D-glucan synthesis. Med Mycol 39, 
Suppl 1)55–66.
Drgonová J, Drgon T, Roh DH, Cabib E (1999). The GTP-binding protein 
Rho1p is required for cell cycle progression and polarization of the yeast 
cell. J Cell Biol 146, 373–387.
Drgonová J, Drgon T, Tanaka K, Kollár R, Chen GC, Ford RA, Chan CS, Takai 
Y, Cabib E (1996). Rho1p, a yeast protein at the interface between cell 
polarization and morphogenesis. Science 272, 277–279.
Gómez-Esquer F, Rodríguez-Peña JM, Díaz G, Rodriguez E, Briza P, 
Nombela C, Arroyo J (2004). CRR1, a gene encoding a putative trans-
glycosidase, is required for proper spore wall assembly in Saccharomyces 
cerevisiae. Microbiology 150, 3269–3280.
Hashimoto H, Yoda K (1997). Novel membrane protein complexes for 
protein glycosylation in the yeast Golgi apparatus. Biochem Biophys Res 
Commun 241, 682–686.
Healey KR, Katiyar SK, Raj S, Edlind TD (2012). CRS-MIS in Candida 
glabrata: sphingolipids modulate echinocandin-Fks interaction. Mol 
Microbiol 86, 303–313.
Inoue SB, Takewaki N, Takasuka T, Mio T, Adachi M, Fujii Y, Miyamoto C, 
Arisawa M, Furuichi Y, Watanabe T (1995). Characterization and gene 
cloning of 1,3-beta-D-glucan synthase from Saccharomyces cerevisiae. 
Eur J Biochem 231, 845–854.
Iwaki A, Ohnuki S, Suga Y, Izawa S, Ohya Y (2013). Vanillin inhibits transla-
tion and induces messenger ribonucleoprotein (mRNP) granule 
formation in Saccharomyces cerevisiae: application and validation of 
high-content, image-based profiling. PLoS One 8, e61748.
Jigami Y (2008). Yeast glycobiology and its application. Biosci Biotechnol 
Biochem 72, 637–648.
Johnson ME, Edlind TD (2012). Topological and mutational analysis of 
Saccharomyces cerevisiae Fks1. Eukaryot Cell 11, 952–960.
Johnson ME, Katiyar SK, Edlind TD (2011). New Fks hot spot for acquired 
echinocandin resistance in Saccharomyces cerevisiae and its contribu-
tion to intrinsic resistance of Scedosporium species. Antimicrob Agents 
Chemother 55, 3774–3781.
Jonckheere AR (1954). A test of significance for the relation between M 
rankings and K ranked categories. Br J Stat Psychol 7, 93–100.
Jungmann J, Munro S (1998). Multi-protein complexes in the cis Golgi of 
Saccharomyces cerevisiae with alpha-1,6-mannosyltransferase activity. 
EMBO J 17, 423–434.
Jungmann J, Rayner JC, Munro S (1999). The Saccharomyces cerevisiae 
protein Mnn10p/Bed1p is a subunit of a Golgi mannosyltransferase 
complex. J Biol Chem 274, 6579–6585.
Klis FM, Boorsma A, De Groot PWJ (2006). Cell wall construction in 
Saccharomyces cerevisiae. Yeast 23, 185–202.
Kollár R, Reinhold BB, Petráková E, Yeh HJ, Ashwell G, Drgonová J, 
Kapteyn JC, Klis FM, Cabib E (1997). Architecture of the yeast cell wall. 
Beta(1→6)-glucan interconnects mannoprotein, beta(1→)3-glucan, and 
chitin. J Biol Chem 272, 17762–17775.
Lagunas R, DeJuan C, Benito B (1986). Inhibition of biosynthesis of 
Saccharomyces cerevisiae sugar transport system by tunicamycin. 
J Bacteriol 168, 1484–1486.
Latgé J-P (2007). The cell wall: a carbohydrate armour for the fungal cell. 
Mol Microbiol 66, 279–290.
Lesage G, Bussey H (2006). Cell wall assembly in Saccharomyces cerevisiae. 
Microbiol Mol Biol Rev 70, 317–343.
REFERENCES
Arnold E, Tanner W (1982). An obligatory role of protein glycosylation in the 
life cycle of yeast cells. FEBS Lett 148, 49–53.
Ballou CE (1990). Isolation, characterization, and properties of Saccharomy-
ces cerevisiae mnn mutants with nonconditional protein glycosylation 
defects. Methods Enzymol 185, 440–470.
Barnes G, Hansen WJ, Holcomb CL, Rine J (1984). Asparagine-linked glyco-
sylation in Saccharomyces cerevisiae: genetic analysis of an early step. 
Mol Cell Biol 4, 2381–2388.
Volume 25 January 15, 2014 Yeast cell wall in cell morphology | 233 
Ram AF, Kapteyn JC, Montijn RC, Caro LH, Douwes JE, Baginsky W, Mazur 
P, van den Ende H, Klis FM (1998). Loss of the plasma membrane-bound 
protein Gas1p in Saccharomyces cerevisiae results in the release of 
beta1,3-glucan into the medium and induces a compensation mecha-
nism to ensure cell wall integrity. J Bacteriol 180, 1418–1424.
Rodríguez-Peña JM, Cid VJ, Arroyo J, Nombela C (2000). A novel family of 
cell wall-related proteins regulated differently during the yeast life cycle. 
Mol Cell Biol 20, 3245–3255.
Rodríguez-Peña JM, Rodriguez C, Alvarez A, Nombela C, Arroyo J (2002). 
Mechanisms for targeting of the Saccharomyces cerevisiae GPI-an-
chored cell wall protein Crh2p to polarised growth sites. J Cell Sci 115, 
2549–2558.
Roemer T, Bussey H (1991). Yeast beta-glucan synthesis: KRE6 encodes a 
predicted type II membrane protein required for glucan synthesis in 
vivo and for glucan synthase activity in vitro. Proc Natl Acad Sci USA 88, 
11295–11299.
Saito TL, Ohtani M, Sawai H, Sano F, Saka A, Watanabe D, Yukawa M, Ohya 
Y, Morishita S (2004). SCMD: Saccharomyces cerevisiae Morphological 
Database. Nucleic Acids Res 32, D319–22.
Sambrook J, Fritsch EF, Maniatis T (1989). Molecular Cloning: A Laboratory 
Manual, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
Santos B, Duran A, Valdivieso MH (1997). CHS5, a gene involved in chitin 
synthesis and mating in Saccharomyces cerevisiae. Mol Cell Biol 17, 
2485–2496.
Santos B, Snyder M (1997). Targeting of chitin synthase 3 to polarized 
growth sites in yeast requires Chs5p and Myo2p. J Cell Biol 136, 95–110.
Sawistowska-Schröder ET, Kerridge D, Perry H (1984). Echinocandin inhibi-
tion of 1,3-β-D-glucan synthase from Candida albicans. FEBS Lett 173, 
134–138.
Schmidt M, Strenk ME, Boyer MP, Fritsch BJ (2005). Importance of cell wall 
mannoproteins for septum formation in Saccharomyces cerevisiae. Yeast 
22, 715–723.
Schmidt M, Varma A, Drgon T, Bowers B, Cabib E (2003). Septins, under 
Cla4p regulation, and the chitin ring are required for neck integrity in 
budding yeast. Mol Biol Cell 14, 2128–2141.
Snyder M (1989). The SPA2 protein of yeast localizes to sites of cell growth. 
J Cell Biol 108, 1419–1429.
van Berkel MA, Rieger M, te Heesen S, Ram AF, van den Ende H, Aebi M, 
Klis FM (1999). The Saccharomyces cerevisiae CWH8 gene is required 
for full levels of dolichol-linked oligosaccharides in the endoplasmic 
reticulum and for efficient N-glycosylation. Glycobiology 9, 243–253.
van Drogen F, Peter M (2002). Spa2p functions as a scaffold-like protein to 
recruit the Mpk1p MAP kinase module to sites of polarized growth. Curr 
Biol 12, 1698–1703.
Yoshida M, Ohnuki S, Yashiroda Y, Ohya Y (2013). Profilin is required for Ca2+ 
homeostasis and Ca2+-modulated bud formation in yeast. Mol Genet 
Genomics 288, 317–328.
Levy SF, Siegal ML (2008). Network hubs buffer environmental variation in 
Saccharomyces cerevisiae. PLoS Biol 6, e264.
Mrsa V, Ecker M, Strahl-Bolsinger S, Nimtz M, Lehle L, Tanner W (1999). 
Deletion of new covalently linked cell wall glycoproteins alters the elec-
trophoretic mobility of phosphorylated wall components of Saccharomy-
ces cerevisiae. J Bacteriol 181, 3076–3086.
Nishiyama Y, Uchida K, Yamaguchi H (2002). Morphological changes 
of Candida albicans induced by micafungin (FK463), a water-soluble 
echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 51, 
247–255.
Ohnuki S, Kobayashi T, Ogawa H, Kozone I, Ueda J-Y, Takagi M, Shin-Ya K, 
Hirata D, Nogami S, Ohya Y (2012). Analysis of the biological activity of 
a novel 24-membered macrolide JBIR-19 in Saccharomyces cerevisiae 
by the morphological imaging program CalMorph. FEMS Yeast Res 12, 
293–304.
Ohnuki S, Nogami S, Kanai H, Hirata D, Nakatani Y, Morishita S, Ohya Y 
(2007). Diversity of Ca2+-induced morphology revealed by morphologi-
cal phenotyping of Ca2+-sensitive mutants of Saccharomyces cerevisiae. 
Eukaryot Cell 6, 817–830.
Ohnuki S, Oka S, Nogami S, Ohya Y (2010). High-content, image-based 
screening for drug targets in yeast. PLoS One 5, e10177.
Ohtani M, Saka A, Sano F, Ohya Y, Morishita S (2004). Development of im-
age processing program for yeast cell morphology. J Bioinform Comput 
Biol 1, 695–709.
Ohya Y et al. (2005). High-dimensional and large-scale phenotyping of yeast 
mutants. Proc Natl Acad Sci USA 102, 19015–19020.
Okada H, Abe M, Asakawa-Minemura M, Hirata A, Qadota H, Morishita 
K, Ohnuki S, Nogami S, Ohya Y (2010). Multiple functional domains of 
the yeast l,3-β-glucan synthase subunit Fks1p revealed by quantitative 
phenotypic analysis of temperature-sensitive mutants. Genetics 184, 
1013–1024.
Orlean P (2012). Architecture and biosynthesis of the Saccharomyces cerevi-
siae cell wall. Genetics 192, 775–818.
Orłowski J, Machula K, Janik A, Zdebska E, Palamarczyk G (2007). Dis-
secting the role of dolichol in cell wall assembly in the yeast mutants 
impaired in early glycosylation reactions. Yeast 24, 239–252.
Perlin DS (2007). Resistance to echinocandin-class antifungal drugs. Drug 
Resist Updat 10, 121–130.
Popolo L, Vai M (1999). The Gas1 glycoprotein, a putative wall polymer 
cross-linker. Biochim Biophys Acta 1426, 385–400.
Qadota H, Python CP, Inoue SB, Arisawa M, Anraku Y, Zheng Y, Watanabe 
T, Levin DE, Ohya Y (1996). Identification of yeast Rho1p GTPase as a 
regulatory subunit of 1,3-beta-glucan synthase. Science 272, 279–281.
Ragni E, Piberger H, Neupert C, García-Cantalejo J, Popolo L, Arroyo J, 
Aebi M, Strahl S (2011). The genetic interaction network of CCW12, a 
Saccharomyces cerevisiae gene required for cell wall integrity during 
budding and formation of mating projections. BMC Genomics 12, 107.
